The short version of insulin-like growth factor 1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-01. Anything still debated is marked as such rather than presented as settled.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility | Soluble in water | Consistent with peptide nature |
| Typical storage | 2 to 8 degrees Celsius | Refrigerated, dry, protected from light |
| Common analytical method | Reversed-phase HPLC | Purity and impurity profiling |
| Identity confirmation | Mass spectrometry | Molecular mass verification |
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
=== Train of four ratio test === The train of four ratio (i.e., ToFr) is a neuromuscular test for monitoring neuromuscular function (see monitoring neuromuscular blockade). In this test, a peripheral nerve (most commonly the ulnar nerve) is stimulated by an electrical impulse 4 times (i.e., T1, T2, T3, T4) and the strength of contraction is measured in a muscle(s) (i.e., the abductor pollicis longus and brevis muscles for the ulnar nerve). The ratio of the amplitude of muscle contraction in response to the fourth impulse (T4) divided by the amplitude of muscle contraction in response to the first impulse is calculated. The ratio of these two contractions should be 1.0. Values less than this are regarded as abnormal. ToFr is used to determine when the effects of an administered neuromuscular-blocking drug have worn off (see postoperative residual curarization) or as the most objective, accurate, and sensitive test for determining the presence and severity of myasthenia gravis: myasthenia gravis is considered to afflict the tested muscle if its ToFr ratio (i.e., T4/T1) is less than 0.9.
The Energy Performance of Buildings Directive 2010 aims to eliminate unclean materials and energy waste to have "nearly zero-energy buildings", particularly by setting standards for new buildings since 2020 and upgrading existing buildings by 2050. There is, however, no requirement yet that all buildings replace gas heating with electric or heat-pumps, have solar or wind energy generation, electric vehicle charging, and particular insulation standards, wherever possible.
Myocardial disarray, also known as myocyte disarray, is a term to describe the loss of the normal parallel alignment of myocytes (the muscle cells of the heart). Instead, the myocytes usually form circles around foci of connective tissue. Myocardial disarray is associated with myocardial fibrosis (the replacement of the myocytes with non-contractile scar tissue). Myocardial disarray can be seen in a number of disease states, including:
=== Recovery supplements === Common supplements to help athletes recover from exercising include protein and amino acid supplements. The main use for athletes to take dietary proteins are enhance muscle repair and growth. The intake of protein is a part of the nutrient requirements for the normal athlete and is an important component of exercise training. In addition, it aids in performance and recovery. A 2018 meta-review recommended that individuals may take up to 1.6 g/kg/day of protein with a confidence interval spanning from 1.03 to 2.20 so “it may be prudent to recommend ~2.2 g protein/kg/d for those seeking to maximise resistance training-induced gains in FFM.”. FFM is an abbreviation for fat free mass. Dietary protein intake for well-trained athletes should occur before, during and after physical activity as it is advantageous in gaining muscle mass and strength. In healthy individuals with good kidney function there is no evidence that consuming a high protein diet has any deleterious effects. A bountiful protein diet must be paired with a healthy, well-rounded meal plan and regular resistance exercise. Characteristics of this particular diet include the type of exercise, intensity, duration and carbohydrate values of diet. Post-exercise nutrition is an important factor in a nutrition plan for athletes as it pertains to the recovery of the body. Traditionally, sports drinks such as Gatorade and Powerade, are consumed during and after exercise because they effectively rehydrate the body by refueling the body with carbohydrates, minerals and electrolytes.
Sources: en.wikipedia.org
Although vitamin A is necessary for fetal development, most women carry sufficient stores of vitamin A in their liver cells, so over-supplementation should be strictly avoided. A review of all randomized controlled trials in the scientific literature by the Cochrane Collaboration published in JAMA in 2007 found that supplementation with beta carotene or vitamin A increased mortality by 5% and 16%, respectively. This effect has been attributed to the role of retinol and retinoic acid in increasing circulating cholesterol and triglycerides as well as promoting cancer incidence. Studies emerging from developing countries India, Bangladesh, and Indonesia strongly suggest that, in populations in which vitamin A deficiency is common and maternal mortality is high, dosing expectant mothers with retinol can greatly reduce maternal mortality. Similarly, dosing newborn infants with 50,000 IU (15 mg) of vitamin A within two days of birth can significantly reduce neonatal mortality.
In the 1969 election, the SPD gained enough votes to form a coalition government with the FDP. SPD leader and Chancellor Willy Brandt remained head of government until May 1974, when he resigned after the Guillaume affair, in which a senior member of his staff was uncovered as a spy for the East German intelligence service, the Stasi. However, the affair is widely considered to have been merely a trigger for Brandt's resignation, not a fundamental cause. Instead, Brandt, dogged by scandal relating to alcohol and depression as well as the economic fallout of the 1973 oil crisis, almost seems simply to have had enough. As Brandt himself later said, "I was exhausted, for reasons which had nothing to do with the process going on at the time". Finance Minister Helmut Schmidt (SPD) then formed a government, continuing the SPD–FDP coalition. He served as Chancellor from 1974 to 1982. Hans-Dietrich Genscher, a leading FDP official, was Vice-Chancellor and Foreign Minister in the same years. Schmidt, a strong supporter of the European Community (EC) and the Atlantic alliance, emphasised his commitment to "the political unification of Europe in partnership with the USA". The goals of SPD and FDP drifted apart in the late 1970s and early 1980s. On 1 October 1982 the FDP joined forces with the CDU/CSU to elect CDU Chairman Helmut Kohl as Chancellor in a constructive vote of no confidence. Following national elections in March 1983, Kohl emerged in firm control of both the government and the CDU.
==== MeSH D12.776.964.775.350 – gene products, gag (gene) ==== MeSH D12.776.964.775.350.320 – fusion proteins, gag-onc MeSH D12.776.964.775.350.320.700 – oncogene protein p65(gag-jun) MeSH D12.776.964.775.350.325 – fusion proteins, gag-pol MeSH D12.776.964.775.350.400 – hiv core protein p24
Sources: en.wikipedia.org
== Medical uses == Meprobamate is indicated for the short-term relief of anxiety, although whether the purported anxiolytic effects of meprobamate are separable from its sedative effects is not known. Its effectiveness as a selective agent for the treatment of anxiety has not been proven in humans, and is not used as often as the benzodiazepines for this purpose. Meprobamate is available in 200- and 400-mg tablets for oral administration. It is also a component of the combination drug Equagesic (discontinued in the UK in 2002), acting as a muscle relaxant.
=== Congeners === Coronaridine congeners are important in drug discovery and development due to multiple actions on different targets. They have ability to inhibit Cav2.2 channel, modulate and inhibit subunits of nAChr selectively such as α9α10, α3β4 and potentiate GABAA activity.
== Further reading == Albert, A.; Serjeant, E.P. (1971). The Determination of Ionization Constants: A Laboratory Manual. Chapman & Hall. ISBN 0-412-10300-1. (Previous edition published as Ionization constants of acids and bases. London (UK): Methuen. 1962.) Atkins, P.W.; Jones, L. (2008). Chemical Principles: The Quest for Insight (4th ed.). W.H. Freeman. ISBN 978-1-4292-0965-6. Housecroft, C. E.; Sharpe, A. G. (2008). Inorganic Chemistry (3rd ed.). Prentice Hall. ISBN 978-0-13-175553-6. (Non-aqueous solvents) Hulanicki, A. (1987). Reactions of Acids and Bases in Analytical Chemistry. Horwood. ISBN 0-85312-330-6. (translation editor: Mary R. Masson) Perrin, D.D.; Dempsey, B.; Serjeant, E.P. (1981). pKa Prediction for Organic Acids and Bases. Chapman & Hall. ISBN 0-412-22190-X. Reichardt, C. (2003). Solvents and Solvent Effects in Organic Chemistry (3rd ed.). Wiley-VCH. ISBN 3-527-30618-8. Chapter 4: Solvent Effects on the Position of Homogeneous Chemical Equilibria. Skoog, D.A.; West, D.M.; Holler, J.F.; Crouch, S.R. (2004). Fundamentals of Analytical Chemistry (8th ed.). Thomson Brooks/Cole. ISBN 0-03-035523-0.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.
Reversed-phase high-performance liquid chromatography is commonly used to separate and quantify the peptide and its impurities. Mass spectrometry is often paired with it to confirm identity. Together they provide a profile of related substances.
Extreme pH values accelerate hydrolytic degradation of the peptide backbone. Buffered solutions in a near-neutral range generally slow this process. Solution age and temperature also affect the rate of breakdown.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.